文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

不同年龄与CKD 1至5D/T期的胱氨酸病相关代谢性骨病

Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项跨国横断面多中心研究纳入103例胱氨酸病患者(61%为儿童),覆盖CKD 1至5D/T期,评估10项骨标志物。结果显示约三分之二患者发生骨骼并发症,成人风险较儿童增加5倍;CKD 1至3期患者血清磷和钙z评分降低,FGF23与甲状旁腺激素受抑,骨特异性碱性磷酸酶升高,sRANKL/OPG比值降低,这些改变在移植后仅部分纠正。

要点

  • 胱氨酸病患者约三分之二发生骨骼并发症,成人风险约为儿童的5倍。
  • CKD 1至3期患者血清磷、钙z评分降低,FGF23与甲状旁腺激素受抑,骨特异性碱性磷酸酶升高。
  • sRANKL/OPG比值降低,移植后这些改变仅部分纠正。

核心结论

  • 胱氨酸病患者的骨骼健康随年龄恶化,与破骨细胞活性增加相关,尽管成骨细胞通过OPG/RANKL存在反向调节;结合巩膜素水平升高和持续的佝偻病/骨软化症,可能促进进行性骨丢失。

研究设计与样本

  • 跨国横断面多中心研究,纳入103例胱氨酸病患者(61%为儿童),CKD分期为1至5D/T期,来自医院门诊,评估10项关键骨标志物。

主要发现

  • 约三分之二的患者发生骨骼并发症,成人风险较儿童增加5倍。
  • CKD 1至3期患者血清磷和钙z评分降低,FGF23和甲状旁腺激素水平受抑,骨特异性碱性磷酸酶水平升高。
  • 血清磷与估算肾小球滤过率、联合磷剂与活性维生素D治疗及天然维生素D补充相关;血清钙与年龄和活性维生素D剂量相关。
  • 巩膜素在儿童中普遍升高,与年龄、FGF23水平及活性维生素D和生长激素治疗相关;破骨细胞标志物抗酒石酸酸性磷酸酶5b升高,与年龄和活性维生素D治疗相关。
  • sRANKL/OPG比值降低,与磷和1,25(OH)2D3水平相关;这些改变在移植后仅部分纠正。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The pathophysiology of cystinosis-associated metabolic bone disease is complex. OBJECTIVE: We hypothesized a disturbed interaction between osteoblasts and osteoclasts. METHODS: This binational cross-sectional multicenter study included 103 patients with cystinosis (61% children) with chronic kidney disease (CKD) stages 1 to 5D/T at hospital clinics. Ten key bone markers were evaluated. RESULTS: Skeletal complications occurred in two-thirds of the patients, with adults having a 5-fold increased risk compared with children. Patients with CKD stages 1 to 3 showed reduced z-scores for serum phosphate and calcium and suppressed fibroblast growth factor 23 (FGF23) and parathyroid hormone levels, in conjunction with elevated bone-specific alkaline phosphatase levels. Serum phosphate was associated with estimated glomerular filtration rate, combined phosphate and active vitamin D treatment, and native vitamin D supplementation, while serum calcium was associated with age and dosage of active vitamin D. Sclerostin was generally elevated in children, and associated with age, FGF23 levels, and treatment with active vitamin D and growth hormone. The osteoclast marker tartrate-resistant acid phosphatase 5b was increased, and associated with age and treatment with active vitamin D. The ratio of soluble ligand of receptor activator of nuclear factor-κB (sRANKL) and osteoprotegerin (OPG), a surrogate for the regulation of osteoclastogenesis by osteoblasts, was decreased and associated with phosphate and 1,25(OH)2D3 levels. These changes were only partly corrected after transplantation. CONCLUSION: Bone health in cystinosis deteriorates with age, which is associated with increased osteoclast activity despite counter-regulation of osteoblasts via OPG/RANKL, which in conjunction with elevated sclerostin levels and persistent rickets/osteomalacia, may promote progressive bone loss.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lahring J, Leifheit-Nestler M, Ewert A, et al. Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T. J Clin Endocrinol Metab. 2025. PMID: 39049782. doi:10.1210/clinem/dgae502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。